Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes - XML Representation

Active as of 2024-11-01

Raw xml | Download


<Evidence xmlns="http://hl7.org/fhir">
  <id value="236978"/>
  <meta>
    <versionId value="61"/>
    <lastUpdated value="2024-10-03T13:11:20.368Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Evidence 236978</b></p><a name="236978"> </a><a name="hc236978"> </a><a name="236978-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 61; Last updated: 2024-10-03 13:11:20+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-comparative-evidence.html">ComparativeEvidence</a></p></div><p><b>url</b>: <a href="Evidence-236978.html">Evidence MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</a></p><p><b>identifier</b>: FEvIR Object Identifier/236978, outcomeId/313964, picoId/85798, sectionId/73215, <a href="http://terminology.hl7.org/6.0.2/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt 

This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: 

Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.

This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.57</p><p><b>version</b>: 2.0.0-ballot</p><p><b>name</b>: Genital_infectionfrom_MAGICapp_313964</p><p><b>title</b>: MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>status</b>: Active</p><p><b>date</b>: 2024-11-01 10:20:00+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication</a>: Evidence Communication</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ComparativeEvidence}">ComparativeEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>Part Of</td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>
</div><p><b>assertion</b>: </p><div><p>SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</p>
</div><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: population</p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes</p>
</div><p><b>note</b>: population</p><p><b>observed</b>: <a href="Group-236947.html">Adults with type 2 diabetes and CVD and CKD</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: exposure</p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category</b>: GLP-1 RA</p><p><b>description</b>: </p><div><p>GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</p>
</div><p><b>note</b>: exposure</p><p><b>observed</b>: <a href="EvidenceVariable-236950.html">GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code</b>: outcome</p><p><b>description</b>: </p><div><p>Genital infection</p>
</div><p><b>note</b>: outcome</p><p><b>observed</b>: <a href="EvidenceVariable-236977.html">Genital infection</a></p></blockquote><p><b>synthesisType</b>: <span title="Codes:">SYSTEMATIC_REVIEW</span></p><p><b>studyDesign</b>: <span title="Codes:{http://hl7.org/fhir/study-design SEVCO:01003}">randomized assignment</span></p><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>Risk Difference 15.8% (CI95 6.4% to 29.9%)</p>
</div><p><b>statisticType</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/statistic-type 0000424}">Risk Difference</span></p><p><b>quantity</b>: 0.158</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style="display: none">*</td><td>2</td><td>1282</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">CI95</span></td><td>0.064-0.299</td></tr></table></blockquote><blockquote><p><b>statistic</b></p><p><b>description</b>: </p><div><p>OR 5.0 (CI95 2.45 to 10.2)</p>
</div><p><b>statisticType</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/statistic-type C16932}">Odds Ratio</span></p><p><b>quantity</b>: 5</p><h3>SampleSizes</h3><table class="grid"><tr><td style="display: none">-</td><td><b>NumberOfStudies</b></td><td><b>NumberOfParticipants</b></td></tr><tr><td style="display: none">*</td><td>2</td><td>1282</td></tr></table><h3>AttributeEstimates</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Range</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">CI95</span></td><td>2.45-10.2</td></tr></table></blockquote><blockquote><p><b>certainty</b></p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/certainty-type Overall}">Overall certainty</span></p><p><b>rating</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/27834 RJCS-2003}">High certainty</span></p><h3>Subcomponents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Rating</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Risk of Bias</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Inconsistency</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Indirectness</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Imprecision</span></td><td><span title="Codes:">NOTSET</span></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Publication Bias</span></td><td><span title="Codes:">NOTSET</span></td></tr></table></blockquote></div>
  </text>
  <url value="https://fevir.net/resources/Evidence/236978"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="236978"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="outcomeId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="313964"/>
  </identifier>
  <identifier>
    <type>
      <text value="picoId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="85798"/>
  </identifier>
  <identifier>
    <type>
      <text value="sectionId"/>
    </type>
    <system value="https://app.magicapp.org/#/guidelines"/>
    <value value="73215"/>
  </identifier>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:2.16.840.1.113883.4.642.40.44.22.57"/>
  </identifier>
  <version value="2.0.0-ballot"/>
  <name value="Genital_infectionfrom_MAGICapp_313964"/>
  <title
         value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
  <status value="active"/>
  <date value="2024-11-01T10:20:00+00:00"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <author>
    <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
  </author>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ComparativeEvidence"/>
        <display value="ComparativeEvidence"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <relatedArtifact>
    <type value="part-of"/>
    <resourceReference>
      <type value="Composition"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display
               value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
    </resourceReference>
  </relatedArtifact>
  <description
               value="This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
  <assertion
             value="SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists."/>
  <variableDefinition>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
      <valueCode value="population"/>
    </extension>
    <description value="Adults with type 2 diabetes"/>
    <note>
      <text value="population"/>
    </note>
    <observed>🔗 
      <reference value="Group/236947"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-population-group-85394-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Adults with type 2 diabetes and CVD and CKD"/>
    </observed>
  </variableDefinition>
  <variableDefinition>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
      <valueCode value="exposure"/>
    </extension>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-comparator-category">
      <valueString value="GLP-1 RA"/>
    </extension>
    <description value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
    <note>
      <text value="exposure"/>
    </note>
    <observed>🔗 
      <reference value="EvidenceVariable/236950"/>
      <type value="EvidenceVariable"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-group-assignment-85394-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"/>
    </observed>
  </variableDefinition>
  <variableDefinition>
    <extension
               url="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition-variable-role-code">
      <valueCode value="outcome"/>
    </extension>
    <description value="Genital infection"/>
    <note>
      <text value="outcome"/>
    </note>
    <observed>🔗 
      <reference value="EvidenceVariable/236977"/>
      <type value="EvidenceVariable"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-313964"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Genital infection"/>
    </observed>
  </variableDefinition>
  <synthesisType>
    <text value="SYSTEMATIC_REVIEW"/>
  </synthesisType>
  <studyDesign>
    <coding>
      <system value="http://hl7.org/fhir/study-design"/>
      <code value="SEVCO:01003"/>
      <display value="randomized assignment"/>
    </coding>
  </studyDesign>
  <statistic>
    <description value="Risk Difference 15.8% (CI95 6.4% to 29.9%)"/>
    <statisticType>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/statistic-type"/>
        <version value="5.0.0-cibuild"/>
        <code value="0000424"/>
        <display value="Risk Difference"/>
      </coding>
    </statisticType>
    <quantity>
      <value value="0.158"/>
    </quantity>
    <sampleSize>
      <numberOfStudies value="2"/>
      <numberOfParticipants value="1282"/>
    </sampleSize>
    <attributeEstimate>
      <type>
        <text value="CI95"/>
      </type>
      <range>
        <low>
          <value value="0.064"/>
        </low>
        <high>
          <value value="0.299"/>
        </high>
      </range>
    </attributeEstimate>
  </statistic>
  <statistic>
    <description value="OR 5.0 (CI95 2.45 to 10.2)"/>
    <statisticType>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/statistic-type"/>
        <version value="5.0.0-cibuild"/>
        <code value="C16932"/>
        <display value="Odds Ratio"/>
      </coding>
    </statisticType>
    <quantity>
      <value value="5"/>
    </quantity>
    <sampleSize>
      <numberOfStudies value="2"/>
      <numberOfParticipants value="1282"/>
    </sampleSize>
    <attributeEstimate>
      <type>
        <text value="CI95"/>
      </type>
      <range>
        <low>
          <value value="2.45"/>
        </low>
        <high>
          <value value="10.2"/>
        </high>
      </range>
    </attributeEstimate>
  </statistic>
  <certainty>
    <type>
      <coding>
        <system value="http://hl7.org/fhir/certainty-type"/>
        <code value="Overall"/>
        <display value="Overall certainty"/>
      </coding>
    </type>
    <rating>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/27834"/>
        <code value="RJCS-2003"/>
        <display value="High certainty"/>
      </coding>
    </rating>
    <subcomponent>
      <type>
        <text value="Risk of Bias"/>
      </type>
      <rating>
        <text value="NOTSET"/>
      </rating>
    </subcomponent>
    <subcomponent>
      <type>
        <text value="Inconsistency"/>
      </type>
      <rating>
        <text value="NOTSET"/>
      </rating>
    </subcomponent>
    <subcomponent>
      <type>
        <text value="Indirectness"/>
      </type>
      <rating>
        <text value="NOTSET"/>
      </rating>
    </subcomponent>
    <subcomponent>
      <type>
        <text value="Imprecision"/>
      </type>
      <rating>
        <text value="NOTSET"/>
      </rating>
    </subcomponent>
    <subcomponent>
      <type>
        <text value="Publication Bias"/>
      </type>
      <rating>
        <text value="NOTSET"/>
      </rating>
    </subcomponent>
  </certainty>
</Evidence>